Prix
Questions fréquentes
Quelle est la capitalisation boursière de Beyond ?
Quel est le bénéfice par action (BPA) de Beyond ?
Quelles sont les évaluations des analystes et le prix cible de l'action Beyond ?
Quel est le chiffre d'affaires de Beyond sur les douze derniers mois ?
Quel est l'EBITDA de Beyond ?
Quel est le flux de trésorerie disponible de Beyond ?
Quel est le bêta à 5 ans de l'action Beyond ?
Combien d'employés compte Beyond, et à quel secteur d'activité appartient-elle ?
Quel est le flottant des actions de Beyond ?
Finances
Capitalisation boursière
37,49 M $USbêta sur 5 ans
-0,22BPA (TTM)
-1,42 $USFree Float
60,38 MRecettes (TTM)
2,34 M $USEBITDA (TTM)
-53,24 M $USCash-flow disponible (TTM)
-55,19 M $USCotation
Notes des analystes
L'objectif de prix est de 11,67 $US et l'action est analysée par 6 analystes.
Acheter
6
Hold
0
Vendre
0
Informations
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. It is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Its approved product and active pipeline of product candidates include LungFit PH, LungFit PRO and LungFit GO.
107
Medical Equipment & Supplies
Soins de santé
Identifiant
ISIN
Ticker primaire